From Analysis:
RNA binding protein dysregulation across ALS FTD and AD
RNA binding protein dysregulation across ALS FTD and AD
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Molecular Mechanism and Rationale
R-loops are three-stranded nucleic acid structures consisting of an RNA-DNA hybrid and a displaced single-strand DNA, which form naturally during transcription when nascent RNA hybridizes back to the template DNA strand. While R-loops serve important physiological functions in transcriptional regulation, DNA repair, and chromatin remodeling, their dysregulation contributes significantly to neurodegeneration through DNA damage accumulation and transcriptional stress. The senataxin (SETX) protein, a 5'-3' helicase encoded by the SETX gene, plays a crucial role in resolving R-loops and maintaining genomic stability.
...AlphaFold predicted structure available for A0A0S2Z520
View AlphaFold StructureAlthough accumulation of DNA damage and genomic instability in resting cells can cause neurodegenerative disorders, our understanding of how transcription produces DNA double-strand breaks (DSBs) is limited. Transcription-blocking topoisomerase I cleavage complexes (TOP1ccs) are frequent events that prime DSB production in non-replicating cells. Here, we report a mechanism of their formation by showing that they arise from two nearby single-strand breaks (SSBs) on opposing DNA strands: one SSB from the removal of transcription-blocking TOP1ccs by the TDP1 pathway and the other from the cleavage of R-loops by endonucleases, including XPF, XPG, and FEN1. Genetic defects in TOP1cc removal (TDP1, PNKP, and XRCC1) or in the resolution of R-loops (SETX) enhance DSB formation and prevent their repair. Such deficiencies cause neurological disorders. Owing to the high frequency of TOP1cc trapping and the widespread distribution of R-loops, these persistent transcriptional DSBs could accumulate
R-loops are RNA-DNA-hybrid-containing nucleic acids with important cellular roles. Deregulation of R-loop dynamics can lead to DNA damage and genome instability1, which has been linked to the action of endonucleases such as XPG2-4. However, the mechanisms and cellular consequences of such processing have remained unclear. Here we identify a new population of RNA-DNA hybrids in the cytoplasm that are R-loop-processing products. When nuclear R-loops were perturbed by depleting the RNA-DNA helicase senataxin (SETX) or the breast cancer gene BRCA1 (refs. 5-7), we observed XPG- and XPF-dependent cytoplasmic hybrid formation. We identify their source as a subset of stable, overlapping nuclear hybrids with a specific nucleotide signature. Cytoplasmic hybrids bind to the pattern recognition receptors cGAS and TLR3 (ref. 8), activating IRF3 and inducing apoptosis. Excised hybrids and an R-loop-induced innate immune response were also observed in SETX-mutated cells from patients with ataxia ocul
Amyotrophic lateral sclerosis (ALS) is a heterogenous neurodegenerative disorder that affects motor neurons and voluntary muscle control1. ALS heterogeneity includes the age of manifestation, the rate of progression and the anatomical sites of symptom onset. Disease-causing mutations in specific genes have been identified and define different subtypes of ALS1. Although several ALS-associated genes have been shown to affect immune functions2, whether specific immune features account for ALS heterogeneity is poorly understood. Amyotrophic lateral sclerosis-4 (ALS4) is characterized by juvenile onset and slow progression3. Patients with ALS4 show motor difficulties by the time that they are in their thirties, and most of them require devices to assist with walking by their fifties. ALS4 is caused by mutations in the senataxin gene (SETX). Here, using Setx knock-in mice that carry the ALS4-causative L389S mutation, we describe an immunological signature that consists of clonally expanded,
With the development and wide usage of CRISPR technology, the presence of R-loop structures, which consist of an RNA-DNA hybrid and a displaced single-strand (ss) DNA, has become well accepted. R-loop structures have been implicated in a variety of circumstances and play critical roles in the metabolism of nucleic acid and relevant biological processes, including transcription, DNA repair, and telomere maintenance. Helicases are enzymes that use an ATP-driven motor force to unwind double-strand (ds) DNA, dsRNA, or RNA-DNA hybrids. Additionally, certain helicases have strand-annealing activity. Thus, helicases possess unique positions for R-loop biogenesis: they utilize their strand-annealing activity to promote the hybridization of RNA to DNA, leading to the formation of R-loops; conversely, they utilize their unwinding activity to separate RNA-DNA hybrids and resolve R-loops. Indeed, numerous helicases such as senataxin (SETX), Aquarius (AQR), WRN, BLM, RTEL1, PIF1, FANCM, ATRX (alpha
R-loops are three-stranded nucleic acid structures with both physiological and pathological roles in cells. R-loop imaging generally relies on detection of the RNA-DNA hybrid component of these structures using the S9.6 antibody. We show that the use of this antibody for imaging can be problematic because it readily binds to double-stranded RNA (dsRNA) in vitro and in vivo, giving rise to nonspecific signal. In contrast, purified, catalytically inactive human RNase H1 tagged with GFP (GFP-dRNH1) is a more specific reagent for imaging RNA-DNA hybrids. GFP-dRNH1 binds strongly to RNA-DNA hybrids but not to dsRNA oligonucleotides in fixed human cells and is not susceptible to binding endogenous RNA. Furthermore, we demonstrate that purified GFP-dRNH1 can be applied to fixed cells to detect hybrids after their induction, thereby bypassing the need for cell line engineering. GFP-dRNH1 therefore promises to be a versatile tool for imaging and quantifying RNA-DNA hybrids under a wide range of
Proteins are manufactured by ribosomes-macromolecular complexes of protein and RNA molecules that are assembled within major nuclear compartments called nucleoli1,2. Existing models suggest that RNA polymerases I and III (Pol I and Pol III) are the only enzymes that directly mediate the expression of the ribosomal RNA (rRNA) components of ribosomes. Here we show, however, that RNA polymerase II (Pol II) inside human nucleoli operates near genes encoding rRNAs to drive their expression. Pol II, assisted by the neurodegeneration-associated enzyme senataxin, generates a shield comprising triplex nucleic acid structures known as R-loops at intergenic spacers flanking nucleolar rRNA genes. The shield prevents Pol I from producing sense intergenic noncoding RNAs (sincRNAs) that can disrupt nucleolar organization and rRNA expression. These disruptive sincRNAs can be unleashed by Pol II inhibition, senataxin loss, Ewing sarcoma or locus-associated R-loop repression through an experimental syst
Senataxin (SETX), an RNA-DNA helicase, accumulates at transcription pause sites through the tumor suppressor BRCA1. Here, we provide mechanistic insight into how SETX-BRCA1 resolves transcription-associated R-loops to prevent deleterious outcomes. Specifically, we show that full-length SETX unwinds R-loops with broad specificity and that the complex of BRCA1 and its obligatory partner BARD1 binds R-loops and stimulates R-loop unwinding by SETX. BRCA1-BARD1 alleviates the inhibitory effect of RAD52 on SETX-mediated R-loop unwinding. We also demonstrate that phosphorylation of Ser642 in SETX promotes its interaction with BRCA1 through the tandem BRCT domain of the latter. Accordingly, mutations impacting the catalytic domain or Ser642 in SETX lead to R-loop accumulation, transcription-replication conflicts, replication fork stalling and DNA double-strand breaks in human cells. Thus, our results delineate the molecular basis for functional synergy between SETX and BRCA1-BARD1 in R-loop re
R-loops play essential physiological roles but also pose a significant threat to genome stability, particularly during replication, by exacerbating transcription-replication conflicts (TRCs). In this study, we have uncovered a critical role of the SMC5/6 complex in resolving TRCs to preserve fork integrity. We identified the SMC5/6 complex as a synthetic lethal partner of senataxin (SETX), an RNA/DNA helicase critical for removing R-loops that arise during replication. We demonstrated that in SETX-deficient cells, the SMC5/6 complex is recruited to TRCs in response to the buildup of DNA supercoiling and facilitates the recruitment of the BLM/TOP3A/RMI1/RMI2 complex (BTRR). Once recruited, BTRR acts to resolve the TRCs in a manner dependent on the catalytic activity of TOP3A. BTRR is also required for FANCM accumulation at TRCs, which activates the FANCD2 pathway to resolve TRCs. These studies underscore the role of SMC5/6 in sensing TRCs and define the SMC5/6-BTRR-FANCM-FANCD2 axis as
The human papillomavirus (HPV) is a small, non-enveloped virus with a circular double-stranded DNA genome. The HPV genome encodes the E2 activator protein, which is required for viral transcription. R-loops are triple-stranded nucleic acid structures that occur when newly synthesized single-stranded RNA anneals to duplex DNA. These structures form during papillomavirus transcription. We and others have demonstrated that resolution of viral R loops is crucial for HPV episomal maintenance. ZPR1 is a zinc finger protein that can recruit SETX to mammalian R-loops to mediate resolution. E2 binds to and recruits SETX, an R-loop helicase, to the viral promoter. We observed E2 in complex with SETX and ZPR1. However, we found that ZPR1 depletion decreased viral R-loops while enhancing cellular R-loops. ZPR1 depletion also increased SETX binding to the viral promoter. These data suggest that ZPR1 is not required for HPV R-loop resolution, in contrast to what has been observed in mammalian cells.
Senataxin (SETX) regulates RNA polymerase II (RNAPII) transcription and helps maintain genome stability, at least partly by suppressing R-loops. However, despite its importance in human disease, the precise function of SETX has remained unclear. Employing the degradation tag system for acute protein depletion, we demonstrate that SETX loss perturbs RNAPII elongation but does not markedly influence transcription termination at the end of genes. Through in vitro reconstitution of elongation, we show that SETX uses ATP-dependent RNA translocation to drive RNAPII forward across challenging DNA sequences, reminiscent of how bacterial ribosomes help mitigate RNAP pausing. In vivo, SETX depletion accordingly results in increased RNAPII pausing or backtracking, particularly during early elongation, with a corresponding, time-dependent local increase in R-loop formation. Together, these findings redefine our understanding of SETX's role in transcription and provide a mechanistic framework for i
The primary role of break-induced replication (BIR) is to repair single-ended double-strand breaks (seDSBs) generated at broken replication forks and eroding telomeres. In this study, we demonstrated that when senataxin (SETX), an RNA/DNA helicase, is defective, hyper-recombination using the BIR mechanism is induced at R-loops/hybrid-accumulated double-ended DSBs (deDSBs), uncovering a role for BIR in the repair of R-loops/hybrids-associated deDSBs. Intriguingly, the loss of SETX not only triggers non-canonical hyper-end resection requiring RAD52 and XPF but also stalls Polα-primase-initiated end-fill DNA synthesis due to the accumulation of RNA/DNA hybrids on single-strand DNA (ssDNA) overhangs at deDSBs. This conflict between fill-in DNA synthesis and accumulated hybrids induces PCNA ubiquitination and PIF1 loading, thereby initiating the BIR mechanism at deDSBs. Hyper-resection further enhances PCNA ubiquitination and PIF1 loading, driving BIR-mediated hyper-recombination. Moreover,
1. Amyotroph Lateral Scler Frontotemporal Degener. 2026 Feb;27(1-2):163-174. doi: 10.1080/21678421.2025.2574681. Epub 2025 Oct 25. Deciphering ALS-linked genetic variants in indian patients using...
1. Cell Rep. 2026 Jan 27;45(1):116828. doi: 10.1016/j.celrep.2025.116828. Epub 2026 Jan 9. N(6)-methyladenosine modification of RNA is regulated by senataxin and E6 to control HPV...
1. Somatosens Mot Res. 2025 May 8:1-8. doi: 10.1080/08990220.2025.2500940. Online ahead of print. Unveiling ten novel SETX mutations: implications for ALS pathogenesis and clinical...
1. J Appl Genet. 2025 Aug 20. doi: 10.1007/s13353-025-01001-2. Online ahead of print. Ataxia and oculomotor apraxia caused by a large-scale deletion in the senataxin gene. Rusecka JM(1)(2)(3),...
1. bioRxiv [Preprint]. 2025 May 19:2024.06.29.601361. doi: 10.1101/2024.06.29.601361. Break-induced replication is activated to repair R-loop-associated double-strand breaks in SETX-deficient...
SETX (senataxin) is an RNA/DNA helicase that has been implicated in transcriptional regulation and the DNA damage response through resolution of R-loop structures. Mutations in SETX result in either of two distinct neurodegenerative disorders. SETX dominant mutations result in a juvenile form of amyotrophic lateral sclerosis (ALS) called ALS4, whereas recessive mutations are responsible for ataxia called ataxia with oculomotor apraxia type 2 (AOA2). How mutations in the same protein can lead to different phenotypes is still unclear. To elucidate AOA2 disease mechanisms, we first examined gene expression changes following SETX depletion. We observed the effects on both transcription and RNA processing, but surprisingly observed decreased R-loop accumulation in SETX-depleted cells. Importantly, we discovered a strong connection between SETX and the macroautophagy/autophagy pathway, reflecting a direct effect on transcription of autophagy genes. We show that SETX depletion inhibits the pr
Amyotrophic lateral sclerosis 4 (ALS4) is an autosomal dominant motor neuron disease that is molecularly characterized by reduced R-loop levels and caused by pathogenic variants in senataxin (SETX). SETX encodes an RNA/DNA helicase that resolves three-stranded nucleic acid structures called R-loops. Currently, there are no disease-modifying therapies available for ALS4. Given that SETX is haplosufficient, removing the product of the mutated allele presents a potential therapeutic strategy. We designed a series of siRNAs to selectively target the RNA transcript from the ALS4 allele containing the c.1166T>C mutation (p.Leu389Ser). Transfection of HEK293 cells with siRNA and plasmids encoding either wild-type or mutant (Leu389Ser) epitope-tagged SETX revealed that three siRNAs specifically reduced mutant SETX protein levels while having minimal effect on the wild-type SETX protein. In ALS4 primary fibroblasts, siRNA treatment silenced the endogenous mutant SETX allele while sparing the wi
The RNA/DNA helicase senataxin (SETX) has been involved in multiple crucial processes related to genome expression and integrity such us transcription termination, the regulation of transcription-replication conflicts and the resolution of R-loops. SETX has been the focus of numerous studies since the discovery that mutations in its coding gene are the root cause of two different neurodegenerative diseases: Ataxia with Oculomotor Apraxia type 2 (AOA2) and a juvenile form of Amyotrophic Lateral Sclerosis (ALS4). A plethora of cellular phenotypes have been described as the result of SETX deficiency, yet the precise molecular function of SETX as well as the molecular pathways leading from SETX mutations to AOA2 and ALS4 pathologies have remained unclear. However, recent data have shed light onto the biochemical activities and biological roles of SETX, thus providing new clues to understand the molecular consequences of SETX mutation. In this review we summarize near two decades of scienti
Senataxin is an RNA:DNA helicase that plays an important role in the resolution of RNA:DNA hybrids (R-loops) formed during transcription. R-loops are involved in the regulation of biological processes such as immunoglobulin class switching, gene expression and DNA repair. Excessive accumulation of R-loops results in DNA damage and loss of genomic integrity. Senataxin is critical for maintaining optimal levels of R-loops to prevent DNA damage and acts as a genome guardian. Within the nucleus, senataxin interacts with various RNA processing factors and DNA damage response and repair proteins. Senataxin interactors include survival motor neuron and zinc finger protein 1, with whom it co-localizes in sub-nuclear bodies. Despite its ubiquitous expression, mutations in senataxin specifically affect neurons and result in distinct neurodegenerative diseases such as amyotrophic lateral sclerosis type 4 and ataxia with oculomotor apraxia type 2, which are attributed to the gain-of-function and t
R loops are transient three-stranded nucleic acid structures that form physiologically during transcription when a nascent RNA transcript hybridizes with the DNA template strand, leaving a single strand of displaced nontemplate DNA. However, aberrant persistence of R-loops can cause DNA damage by inducing genomic instability. Indeed, evidence has emerged that R-loops might represent a key element in the pathogenesis of human diseases, including cancer, neurodegeneration, and motor neuron disorders. Mutations in genes directly involved in R-loop biology, such as SETX (senataxin), or unstable DNA expansion eliciting R-loop generation, such as C9ORF72 HRE, can cause DNA damage and ultimately result in motor neuron cell death. In this review, we discuss current advancements in this field with a specific focus on motor neuron diseases associated with deregulation of R-loop structures. These mechanisms can represent novel therapeutic targets for these devastating, incurable diseases.
R-loops comprise an RNA/DNA hybrid and a displaced single-stranded DNA. They play crucial biological functions and are implicated in neurological diseases, including ataxias, amyotrophic lateral sclerosis, nucleotide expansion disorders (Friedreich ataxia and fragile X syndrome), and cancer. Currently, it is unclear which mechanisms cause R-loop structures to become pathogenic. The RNA/DNA helicase senataxin (SETX) is one of the best characterised R-loop-binding factors in vivo. Mutations in SETX are linked to two neurodegenerative disorders: ataxia with oculomotor apraxia type 2 (AOA2) and amyotrophic lateral sclerosis type 4 (ALS4). SETX is known to play a role in transcription, neurogenesis, and antiviral response. Here, we review the causes of R-loop dysregulation in neurodegenerative diseases and how these structures contribute to pathomechanisms. We will discuss the importance of SETX as a genome guardian in suppressing aberrant R-loop formation and analyse how SETX mutations can
Amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease (CMT) are two distinct neurodegenerative disorders. While ALS is characterised by rapidly progressive motor neuron degeneration, leading to severe complications and death, CMT as a peripheral neuropathy is less severe, and patients have a longer life span, although with a compromised quality of life. Despite their clinical differences, current knowledge suggests that familial ALS (fALS) and CMT may share common genetic and molecular mechanisms. We aimed to identify shared genes mutations and molecular pathways between fALS and CMT through a literature and database search. Thirteen genes were identified, involved in distinct cellular processes: axonal transport (DYNC1H1, KIF5A, SPG11, DCTN1), protein homeostasis (NEFH, VCP, SOD1), RNA metabolism (GARS, SETX), cellular stress response (HSPB1, FIG4), and mitochondrial function (MFN2, CHCHD10). While these linkages to the two diseases are rare for each gene, understanding
Specific Weaknesses:
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.457 | ▲ 2.0% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.448 | ▲ 4.7% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.428 | ▼ 2.0% | 2026-04-12 05:13 | |
| ⚖ | Recalibrated | $0.437 | ▼ 1.3% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.443 | ▲ 1.5% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.436 | ▼ 2.1% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.445 | ▼ 0.5% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.447 | ▼ 0.7% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.451 | ▼ 2.0% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.460 | ▲ 2.4% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.449 | ▼ 14.0% | 2026-04-03 23:46 | |
| ⚖ | Recalibrated | $0.522 | ▲ 7.2% | market_dynamics | 2026-04-03 01:06 |
| ⚖ | Recalibrated | $0.487 | ▲ 1.7% | market_dynamics | 2026-04-03 01:06 |
| ⚖ | Recalibrated | $0.479 | ▲ 11.9% | 2026-04-02 21:55 | |
| ⚖ | Recalibrated | $0.428 | ▼ 23.2% | market_recalibrate | 2026-04-02 19:14 |
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
SETX["SETX"] -->|catalyzes| R_loop_resolution["R-loop_resolution"]
SETX_1["SETX"] -->|associated with| neurodegeneration["neurodegeneration"]
SETX_2["SETX"] -->|participates in| Senataxin___R_loop_resolu["Senataxin / R-loop resolution / DNA-RNA hybrid"]
SETX_3["SETX"] -->|co discussed| TARDBP["TARDBP"]
SETX_4["SETX"] -->|co discussed| HNRNPA2B1["HNRNPA2B1"]
SETX_5["SETX"] -->|co discussed| NPM1["NPM1"]
SETX_6["SETX"] -->|co discussed| SYNCRIP["SYNCRIP"]
SETX_7["SETX"] -->|co discussed| G3BP1["G3BP1"]
G3BP1_8["G3BP1"] -->|co discussed| SETX_9["SETX"]
NPM1_10["NPM1"] -->|co discussed| SETX_11["SETX"]
TARDBP_12["TARDBP"] -->|co discussed| SETX_13["SETX"]
HNRNPA2B1_14["HNRNPA2B1"] -->|co discussed| SETX_15["SETX"]
G3BP1_16["G3BP1"] -->|co associated with| SETX_17["SETX"]
HNRNPA2B1_18["HNRNPA2B1"] -->|co associated with| SETX_19["SETX"]
NPM1_20["NPM1"] -->|co associated with| SETX_21["SETX"]
style SETX fill:#ce93d8,stroke:#333,color:#000
style R_loop_resolution fill:#81c784,stroke:#333,color:#000
style SETX_1 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style SETX_2 fill:#ce93d8,stroke:#333,color:#000
style Senataxin___R_loop_resolu fill:#81c784,stroke:#333,color:#000
style SETX_3 fill:#ce93d8,stroke:#333,color:#000
style TARDBP fill:#ce93d8,stroke:#333,color:#000
style SETX_4 fill:#ce93d8,stroke:#333,color:#000
style HNRNPA2B1 fill:#ce93d8,stroke:#333,color:#000
style SETX_5 fill:#ce93d8,stroke:#333,color:#000
style NPM1 fill:#ce93d8,stroke:#333,color:#000
style SETX_6 fill:#ce93d8,stroke:#333,color:#000
style SYNCRIP fill:#ce93d8,stroke:#333,color:#000
style SETX_7 fill:#ce93d8,stroke:#333,color:#000
style G3BP1 fill:#ce93d8,stroke:#333,color:#000
style G3BP1_8 fill:#ce93d8,stroke:#333,color:#000
style SETX_9 fill:#ce93d8,stroke:#333,color:#000
style NPM1_10 fill:#ce93d8,stroke:#333,color:#000
style SETX_11 fill:#ce93d8,stroke:#333,color:#000
style TARDBP_12 fill:#ce93d8,stroke:#333,color:#000
style SETX_13 fill:#ce93d8,stroke:#333,color:#000
style HNRNPA2B1_14 fill:#ce93d8,stroke:#333,color:#000
style SETX_15 fill:#ce93d8,stroke:#333,color:#000
style G3BP1_16 fill:#ce93d8,stroke:#333,color:#000
style SETX_17 fill:#ce93d8,stroke:#333,color:#000
style HNRNPA2B1_18 fill:#ce93d8,stroke:#333,color:#000
style SETX_19 fill:#ce93d8,stroke:#333,color:#000
style NPM1_20 fill:#ce93d8,stroke:#333,color:#000
style SETX_21 fill:#ce93d8,stroke:#333,color:#000
neurodegeneration | 2026-04-01 | completed